Clinical trials: Recurrent Cancer, open to volunteers
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
CTCL
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell…
- Trial name
- NCT06854653
- Testing
- PTX-100
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 115 people
- Sponsor
- Prescient Therapeutics, Ltd.
Colorectal Cancer Metastatic
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
This project is the first application, which is applied as a single center project and applied according to the screening quantity.
- Trial name
- NCT05501353
- Testing
- no intervention
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Craniopharyngiomas
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1.
- Trial name
- NCT06970145
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
Relapsed/Refractory B-cell Malignancies
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
- Trial name
- NCT06590961
- Testing
- UBX-303061
- Where
- 11 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Ubix Therapeutics, Inc.
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Esophageal Cancer, Recurrence
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor.
- Conditions
- Esophageal Cancer, Recurrence, DNA Methylation
- Trial name
- NCT06476067
- Testing
- Surgery
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Relapsed Cancer, Refractory Multiple Myeloma
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
- Conditions
- Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- ISABELA (NCT05922501)
- Testing
- Isatuximab, Belantamab mafodotin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Recurrent Glioblastoma
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive…
- Trial name
- NCT05540275
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
Relapsed/Refractory B-cell Malignancies
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies.
- Trial name
- NCT07002112
- Testing
- CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement…
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant
- Trial name
- NCT06860594
- Testing
- Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 43 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
HER2-low Breast Cancer
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
- Trial name
- NCT06957886
- Testing
- BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
- Where
- 2 sites in China
- Volunteers
- 566 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Glioblastoma, Recurrent Glioblastoma
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls.
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Trial name
- SONOBIRD (NCT05902169)
- Testing
- SonoCloud-9 (SC9), Carboplatin, Lomustine
- Where
- 56 sites in United States, Austria and 9 more
- Volunteers
- 560 people
- Sponsor
- CarThera
Recurrent Non-small Cell Lung Cancer
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format…
- Trial name
- CCODG-NSCLC (NCT02889666)
- Testing
- Cisplatin, Carboplatin, Docetaxel
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
This is a prospective, single-center, observational study to evaluate the efficacy and safety of salvage haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) combined with post-transplant relapse…
- Conditions
- Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, AML, Relapsed/Refractory
- Trial name
- NCT07572695
- Testing
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT), Post-transplant Maintenance Therapy
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- NCT06635330
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Kara Yakhteh Tajhiz Azma Company
Locally Recurrent Rectal Cancer
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
This is an open-label, single arm, phase 2 study. The study is to evaluate the activity of combination therapy of hypofractionated radiotherapy, Irinotecan Hydrochloride Liposome plus 5-FU and leucovorin (NALIRIF), Anti-PD1 and…
- Trial name
- NCT07183865
- Testing
- radiotherapy, Irinotecan Hydrochloride Liposome, 5-FU
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer
Main objectives: Qualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence/recurrence.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer, Bladder Tumors, Bladder Cancer Recurrence
- Trial name
- LIBERO (NCT06751667)
- Testing
- Urinary biomarkers
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.